Review: artesunate added to standard drug treatment reduces treatment failure in malaria


Clinical impact ratings GP/FP/Primary care Infectious disease Tropical medicine

In patients with acute, uncomplicated Plasmodium falciparum malaria, does the addition of an artemisinin derivative (artesunate) to existing drug treatment reduce treatment failure and transmission potential?

METHODS

Data sources: Medline, Cochrane Central Register of Controlled Trials, and investigators in the field. Individual patient data were requested from the original trial datasets.

Study selection and assessment: randomised controlled trials (RCTs) comparing artesunate plus a standard antimalarial drug with a standard drug alone for acute, uncomplicated P falciparum malaria. Study quality was assessed by adequacy of random allocation, inclusion of all eligible patients in the analysis, and completeness of follow up.

Outcomes: treatment failure rates at 14 and 28 days.

MAIN RESULTS

16 trials met the selection criteria (n = 5948). The background drugs used were chloroquine (3 RCTs done in Burkina Faso, Ivory Coast, and Sao Tome and Prince), amodiaquine (3 RCTs done in Gabon, Kenya, and Senegal), sulphadoxine-pyrimethamine (7 RCTs done in Gambia, Kenya, Malawi, Peru, and Uganda), and mefloquine (3 RCTs done in Thailand). 12 RCTs were placebo controlled. All but 1 RCT assessed 3 days of artesunate. 3 days of artesunate added to background treatment lowered treatment failure more than background treatment alone at 14 and 28 days (table). Gametocytaemia was also reduced with 3 days of artesunate. 3 days of artesunate added to background treatment (odds ratio at 28 d 0.04, 95% CI 0.02 to 0.08).

For correspondence: Professor P Garner, Liverpool School of Tropical Medicine, Liverpool, UK. pgarner@liv.ac.uk

Sources of funding: World Health Organization and Department for International Development UK.

CONCLUSION

In patients with acute, uncomplicated Plasmodium falciparum malaria, the addition of artesunate to existing drug treatment reduces treatment failure.

Commentary

The studies analysed in the review by the International Artemisinin Study Group focus on the reduction of the development of drug resistant malaria in endemic areas. In addition to improving clinical outcomes in malaria endemic countries, the data are also pertinent to practitioners in non-endemic areas because travel to and immigration from these areas are common and imported cases of malaria are seen in practice.

The methods used in this analysis are sound, and the conclusions drawn are reliable. Artesunate, a derivative of a natural product, sweet wormwood, was first developed in China as an antimalarial. The World Health Organization recommends that an artemisinin derivative is included in antimalarial treatment regimes both to improve the clinical response and cure rate and to slow the development of malaria resistance.1 Because artesunate works rapidly to kill most malarial parasites, it leads to a more rapid resolution of fever and can help prevent malaria complications.2,3 The longer half life companion drug kills the malaria parasites that remain.

This product is not currently licensed in the US and therefore may have limited availability. Future research is focused on developing fixed dose combinations including artesunate for treatment of malaria.4

Mary M Fanning, MD, PhD
National Institute of Allergy and Infectious Diseases
Bethesda, Maryland, USA


